-
- Christine Papoushek.
- University Health Network - Toronto Western Hospital, Toronto, ON, Canada.
- J Obstet Gynaecol Can. 2003 Oct 1; 25 (10): 853-7.
AbstractRosiglitazone and pioglitazone are two new additions to the therapeutic options for the treatment of type 2 diabetes mellitus. These agents differ from our current therapies in their mode of action. They have potential non-glucose lowering effects that may reduce cardiovascular risk and are effective both as monotherapy and in combination with sulfonylureas, metformin, and insulin. They are generally well tolerated, with the main side effects being weight gain and fluid retention. However, special precaution is warranted in patients with congestive heart failure or hepatic disease, and monitoring of liver enzymes is recommended for the first year of therapy. Despite their effectiveness, rosiglitazone and pioglitazone remain second-line agents to metformin and glyburide, agents that have demonstrated efficacy in decreasing the microvascular and macrovascular complications associated with type 2 diabetes mellitus.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.